PCM
PASG icon

Penserra Capital Management’s Passage Bio PASG Stock Holding History

Penserra Capital Management’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-62
Closed -$12K – 1498
2021
Q3 		$12K Hold
62
– – ﹤0.01% 1331
2021
Q2 		$16K Buy
62
+2
+3% +$619 ﹤0.01% 1203
2021
Q1 		$20K Buy
60
+8
+15% +$3.42K ﹤0.01% 969
2020
Q4 		$26K Buy
+52
New +$20.8K ﹤0.01% 817

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Penserra Capital Management's PASG Position: Q4 2021 in Review

Penserra Capital Management sold out of Passage Bio (PASG) in Q4 2021, closing a stake of 62 shares — an estimated $12K sold.

Penserra Capital Management first reported a position in PASG in Q4 2020 and held it in 4 quarters. The position peaked at $26K in Q4 2020. 99 funds tracked by Wall St. Rank hold PASG as of Q4 2021.

  • Penserra Capital Management reported no remaining Passage Bio position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 62 Passage Bio shares in Q4 2021, an estimated $12K.
  • Penserra Capital Management first reported a position in Passage Bio in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Passage Bio position peaked at $26K in Q4 2020.
  • 99 funds tracked by Wall St. Rank held Passage Bio as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.